<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Grant</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727983</guid>
      <pubDate>Tue, 13 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727983-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727764</guid>
      <pubDate>Thu, 08 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727764-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725899</guid>
      <pubDate>Tue, 04 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725899-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725777</guid>
      <pubDate>Mon, 03 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725777-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Iveena’s eye drop for myopia receives NEI funding</title>
      <description>
        <![CDATA[Iveena Delivery Systems Inc. has been awarded a $2 million phase II Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance the development of novel topical eye drops to control pediatric myopia and other refractive disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724357</guid>
      <pubDate>Fri, 19 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724357-iveenas-eye-drop-for-myopia-receives-nei-funding</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businesswoman-pressing-dollar-sign-on-touch-screen-.webp?t=1620853996" type="image/png" medium="image" fileSize="390855">
        <media:title type="plain">Businesswoman pressing dollar sign on touchscreen</media:title>
      </media:content>
    </item>
    <item>
      <title>NIH leads grant funding as awards top $1.1B in 2025</title>
      <description>
        <![CDATA[Nonprofit dealmaking in biopharma has been limited in 2025, with total disclosed value reaching just $99.7 million through July. Nearly all of that came in January, when deals totaled $96.9 million. After a quiet first quarter, modest activity resumed with $1.4 million in April and $1.6 million in July, while the other months saw no reported nonprofit partnerships.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722754</guid>
      <pubDate>Fri, 01 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722754-nih-leads-grant-funding-as-awards-top-11b-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Entos awarded CIRM grant to advance ENTLEP-001 for congenital generalized lipodystrophy</title>
      <description>
        <![CDATA[Entos Pharmaceuticals Inc. has been awarded a $4 million grant by California Institute for Regenerative Medicine (CIRM) to support the completion of IND-enabling activities with ENTLEP-001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717032</guid>
      <pubDate>Thu, 06 Feb 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717032-entos-awarded-cirm-grant-to-advance-entlep-001-for-congenital-generalized-lipodystrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>2024 nonprofit deals plummet from pandemic peak</title>
      <description>
        <![CDATA[Biopharma nonprofit deals remained low in 2024, compared to the pandemic and pre-pandemic years, while grants saw a slight decline from the previous year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716871</guid>
      <pubDate>Fri, 31 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716871-2024-nonprofit-deals-plummet-from-pandemic-peak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Ymmunobio and Paul Scherrer Institute advance radioactive loaded antibodies</title>
      <description>
        <![CDATA[Ymmunobio AG, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop innovative radioactive loaded antibodies for the treatment and diagnosis of solid tumors based on Ymmunobio’s proprietary YB-800.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716610</guid>
      <pubDate>Fri, 24 Jan 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716610-ymmunobio-and-paul-scherrer-institute-advance-radioactive-loaded-antibodies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/radioactive-antibody.webp?t=1737734122" type="image/jpeg" medium="image" fileSize="126933">
        <media:title type="plain">Illustration of antibody carrying radioactive isotope</media:title>
      </media:content>
    </item>
    <item>
      <title>Steady gains in biopharma deals as grants see sharp year-over-year increase</title>
      <description>
        <![CDATA[Through September 2024, biopharma firms secured $720.56 million in nonprofit deals, up in value through July and also marking a 21% rise from the $593.23 million in the first three quarters of 2023, though still falling short of 2019-2022 levels. Grants saw an even sharper surge, jumping 131% year-over-year from $1.66 billion to $3.84 billion in the same period, falling short only of 2020 in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714124</guid>
      <pubDate>Fri, 01 Nov 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/714124-steady-gains-in-biopharma-deals-as-grants-see-sharp-year-over-year-increase</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants reach four-year high of $2.5B; nonprofit deals down</title>
      <description>
        <![CDATA[Through July 2024, biopharma firms received $2.52 billion in grants, marking a 52% increase from $1.66 billion in grants during the same period last year. However, nonprofit deals are at their lowest level on record, according to <em>BioWorld’s </em>records. Although nonprofit deal values were initially higher in April compared to 2023, they have since dropped and are now well below the levels seen in prior years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712163</guid>
      <pubDate>Fri, 30 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712163-biopharma-grants-reach-four-year-high-of-25b-nonprofit-deals-down</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>US DoD grant supports Kevirx’s development of drug for acute lung injury</title>
      <description>
        <![CDATA[Kevirx Inc. has been awarded nearly $2 million in grant funding from the U.S. Department of Defense (DoD)’s peer-reviewed medical research program.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709396</guid>
      <pubDate>Wed, 12 Jun 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709396-us-dod-grant-supports-kevirxs-development-of-drug-for-acute-lung-injury</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-anatomy.webp?t=1691698481" type="image/jpeg" medium="image" fileSize="421630">
        <media:title type="plain">Lungs anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems</title>
      <description>
        <![CDATA[Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708533</guid>
      <pubDate>Thu, 16 May 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708533-grant-supports-lift-biosciences-evaluation-of-iman-cell-therapies-in-humanized-in-vivo-model-systems</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-vessels.webp?t=1691420296" type="image/jpeg" medium="image" fileSize="242637">
        <media:title type="plain">3D illustration of tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>LLS grant supports immunotherapy work at University of Washington for hematologic cancers</title>
      <description>
        <![CDATA[Researchers at Washington University School of Medicine in St. Louis have received a $5 million grant from the Leukemia & Lymphoma Society (LLS) to support research aimed at developing new immunotherapies for different types of blood-based cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708451</guid>
      <pubDate>Mon, 13 May 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708451-lls-grant-supports-immunotherapy-work-at-university-of-washington-for-hematologic-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-T-Lymphocyte.webp?t=1715611906" type="image/png" medium="image" fileSize="958813">
        <media:title type="plain">Colorized scanning electron micrograph of a T lymphocyte.</media:title>
        <media:description type="plain">T lymphocyte. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants soar to $6.11B in 2023 while nonprofit deal value falls by 90%</title>
      <description>
        <![CDATA[Biopharma grants maintained their upward trajectory throughout 2023, culminating in a nearly 67% increase in value compared to 2022, mirroring the trend observed in October. Conversely, nonprofit deal value witnessed a continued year-over-year decline, falling by more than 90% in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706115</guid>
      <pubDate>Fri, 01 Mar 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706115-biopharma-grants-soar-to-611b-in-2023-while-nonprofit-deal-value-falls-by-90</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title> Limmatech’s gonorrhea vaccine candidate supported by CARB-X funding</title>
      <description>
        <![CDATA[Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded US$ 2.2 million to Limmatech Biologics AG to advance the development of its novel vaccine candidate to prevent <em>Neisseria gonorrhoeae</em> infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705767</guid>
      <pubDate>Tue, 27 Feb 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705767-limmatechs-gonorrhea-vaccine-candidate-supported-by-carb-x-funding</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Clinical-trial-syringe-and-vial.webp?t=1588960019" type="image/png" medium="image" fileSize="366118">
        <media:title type="plain">Syringe and vial</media:title>
      </media:content>
    </item>
    <item>
      <title>Grant supports Cantabio’s development of DJ-1 protein replacement therapy for Parkinson’s disease</title>
      <description>
        <![CDATA[Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705420</guid>
      <pubDate>Wed, 07 Feb 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705420-grant-supports-cantabios-development-of-dj-1-protein-replacement-therapy-for-parkinsons-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Domain Therapeutics awarded consortium grant to advance DT-7012 toward clinic</title>
      <description>
        <![CDATA[Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).]]>
      </description>
      <guid>http://www.bioworld.com/articles/705097</guid>
      <pubDate>Mon, 29 Jan 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705097-domain-therapeutics-awarded-consortium-grant-to-advance-dt-7012-toward-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/dollar-idea-lightbulb.webp?t=1588794062" type="image/png" medium="image" fileSize="331510">
        <media:title type="plain">Dollar sign in lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>DoD grant supports Factor Bioscience's development of gene-edited cell therapies</title>
      <description>
        <![CDATA[Factor Bioscience Inc. has been awarded a grant by the U.S. Department of Defense to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704526</guid>
      <pubDate>Fri, 12 Jan 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704526-dod-grant-supports-factor-biosciences-development-of-gene-edited-cell-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/CRISPR.webp?t=1626208267" type="image/png" medium="image" fileSize="505117">
        <media:title type="plain">Gene editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants see 75% growth YOY, while nonprofit deals decline</title>
      <description>
        <![CDATA[Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703464</guid>
      <pubDate>Tue, 05 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703464-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants see 75% growth YOY, while nonprofit deals decline</title>
      <description>
        <![CDATA[Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703424</guid>
      <pubDate>Fri, 01 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703424-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title> Biopharmas receive $1.43B in BARDA grants in 2023</title>
      <description>
        <![CDATA[Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions down 42.21%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700664</guid>
      <pubDate>Tue, 05 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700664-biopharmas-receive-143b-in-barda-grants-in-2023</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Feinstein snaps up grant to study rTMS for schizophrenia</title>
      <description>
        <![CDATA[The Feinstein Institutes for Medical Research, the research arm of Northwell Health, landed a $3.4 million grant from the Wellcome Trust to evaluate the use of transcranial magnetic stimulation (rTMS) for schizophrenia. Feinstein will undertake a five-year, double-blind, randomized trial to see whether rTMS improves cognitive or other symptoms of schizophrenia. The technology currently has FDA approval for use in individuals with depression and obsessive-compulsive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/696549</guid>
      <pubDate>Mon, 01 May 2023 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/696549-feinstein-snaps-up-grant-to-study-rtms-for-schizophrenia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/shared-risk---hero.webp?t=1682978761" type="image/jpeg" medium="image" fileSize="219219">
        <media:title type="plain">Illustration of schizophrenia</media:title>
        <media:description type="plain">Credit: Darryl Leja, NHGRI</media:description>
      </media:content>
    </item>
    <item>
      <title>Bio/nonprofit deals slow as grants pick up in second half of 2022</title>
      <description>
        <![CDATA[As the biopharma industry moves away from the COVID-19 pandemic and expands research in other areas, the amount of money flowing into companies through deals with nonprofit or government entities and grants has plummeted 53% in comparison with 2021. The drop is mainly due to a diminishing number and a lower overall value of bio/nonprofit partnerships. Grants, on the other hand, have risen in both areas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692802</guid>
      <pubDate>Tue, 27 Dec 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692802-bio-nonprofit-deals-slow-as-grants-pick-up-in-second-half-of-2022</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio/nonprofit deals slow, grants pick up, in 2022’s second half</title>
      <description>
        <![CDATA[The number of biopharma deals with nonprofit or government entities has dwindled in recent months, while industry grants are climbing. Combined, however, a total of 936 bio/nonprofit deals and grants worth $11.17 billion is down by 37% in comparison with last year’s $17.8 billion and by 58.7% in comparison with 2020’s $27 billion. The volume also is down significantly by 16.8% from 2021 and by 33.4% from 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691625</guid>
      <pubDate>Tue, 15 Nov 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691625-bio-nonprofit-deals-slow-grants-pick-up-in-2022s-second-half</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio-nonprofit deal and grant value of $10.8B down by 22%</title>
      <description>
        <![CDATA[While biopharma grants and company deals with nonprofits and government entities have dropped below each of the last two years, the volume of activity for non-pandemic-related efforts has remained steady. A total of 837 biopharma-nonprofit deals and grants combined so far this year are worth $10.8 billion, which is down by 21.6% over last year’s $13.7 billion and by 15.6% over 2021’s 992 volume. Also down are the deals and grants focused on the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690624</guid>
      <pubDate>Fri, 14 Oct 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690624-bio-nonprofit-deal-and-grant-value-of-108b-down-by-22</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-dollar-down-arrow.webp?t=1638399008" type="image/png" medium="image" fileSize="527882">
        <media:title type="plain">Red arrow down on money background</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grant and nonprofit deal values plunge</title>
      <description>
        <![CDATA[As the COVID-19 pandemic continues to wind down, the value of biopharma company deals with nonprofit and government entities, as well as grants, are down nearly 64%. Through mid-May 2022, <em>BioWorld</em> has tracked 309 bio/nonprofit deals worth $1.12 billion, and a total of 129 grants valued at $505.85 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519118</guid>
      <pubDate>Tue, 24 May 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519118-biopharma-grant-and-nonprofit-deal-values-plunge</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-coins-and-red-down-arrow.webp?t=1644270925" type="image/png" medium="image" fileSize="195704">
        <media:title type="plain">Gold coins and red down arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Nonprofit deal and grant activity focused on pandemic falls by 68%</title>
      <description>
        <![CDATA[The number of biopharma deals with nonprofits or government entities has dropped over last year, partly due to fewer COVID-19-related alliances, but the activity in 2022 is still strong in comparison to pre-pandemic years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516078</guid>
      <pubDate>Tue, 15 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516078-nonprofit-deal-and-grant-activity-focused-on-pandemic-falls-by-68</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Top 10 nonprofit deals all for COVID-19, primarily US government pacts</title>
      <description>
        <![CDATA[Similar to 2020, the COVID-19 pandemic has dominated both biopharma deals with nonprofit entities and grants in 2021. Combined, pandemic deals and grants account for 87% of the total value, but only 22% of the volume, for the year. Through the week of Christmas, <em>BioWorld</em> has recorded 388 grants for the industry, valued at $2.94 billion, and 845 bio/nonprofit deals worth $21.44 billion. Of those, 82 grants worth $1.4 billion and 194 deals worth $19.8 billion involved therapeutic and vaccine development or supply agreements for COVID-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514677</guid>
      <pubDate>Wed, 29 Dec 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514677-top-10-nonprofit-deals-all-for-covid-19-primarily-us-government-pacts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Women-handshake-with-virology-graphics.webp?t=1640805941" type="image/png" medium="image" fileSize="459084">
        <media:title type="plain">Women handshake with virology graphics</media:title>
      </media:content>
    </item>
    <item>
      <title>Slipping behind last year, nonprofit deals and grants still driven by COVID-19</title>
      <description>
        <![CDATA[Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510762</guid>
      <pubDate>Tue, 24 Aug 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510762-slipping-behind-last-year-nonprofit-deals-and-grants-still-driven-by-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
  </channel>
</rss>
